原标题：雅培TAVI FlexNav输送装置获CE Mark

Abbott wins CE Mark for FlexNav delivery system

(NYSE:ABT) announced today that it won CE Mark approval in Europe for the FlexNav delivery system for its Portico transcatheter aortic valve implantation (TAVI) system.

The Abbott Park, Ill.-based company’s FlexNav delivery system is designed to offer another tool for doctors to treatpatients requiring a transcatheter aortic valve implant by incorporating stability, predictability and placement accuracy in the procedure.

Abbott said in a news release that the approval and launch of the FlexNav delivery system follows the first global implants in a clinical study of its next-generation Navitor TAVI system.

Clinical study data presented in September 2019 revealed that in a Portico U.S. trial, patients who received a Portico valve implanted with FlexNav experienced zero deaths, zero strokes andlow rates of major vascular complications and new permanent pacemaker implantsafter 30 days.

IRCCS Policlinico San Donato (Italy )head of cardiology Dr. Francesco Bedogni, a principal investigator in the U.S.study of FlexNav, said in the release that Abbott’s new delivery system canimprove the implant process even in complex cardiac anatomies.

“Within the field of TAVI, delivery systems often don’t receive the attention of the evolving technology of thevalves themselves, but improvements to a delivery system can result insubstantial benefits to patients,” Abbott structural heart business chiefmedical officer Dr. NeilMoat said . “If we look at the total TAVI procedure, innovationaround both the valve itself and also how it’s delivered during an implant areboth central to improving outcomes.”

Portico and FlexNav are only approved for investigational use in the U.S., as is the Navitor TAVI system, accordingto the news release.

责任编辑：